$2.09
1.46% today
NYSE, Aug 25, 06:38 pm CET
ISIN
US43157M1027
Symbol
HLVX

HilleVax Stock price

$2.06
-0.05 2.37% 1M
+0.23 12.57% 6M
-0.01 0.48% YTD
+0.14 7.29% 1Y
-8.83 81.08% 3Y
-17.03 89.21% 5Y
-17.03 89.21% 10Y
-17.03 89.21% 20Y
NYSE, Closing price Fri, Aug 22 2025
-0.01 0.24%
ISIN
US43157M1027
Symbol
HLVX
Industry

Key metrics

Basic
Market capitalization
$103.3m
Enterprise Value
$-56.3m
Net debt
positive
Cash
$159.6m
Shares outstanding
50.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.9
P/B
0.7
Financial Health
Equity Ratio
80.2%
Return on Equity
-95.3%
ROCE
-31.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-49.7m | $-116.3m
EBIT
$-52.3m | $-33.8m
Net Income
$-71.1m | $-25.1m
Free Cash Flow
$-59.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
64.9% | -12.1%
EBIT
63.6% | 68.4%
Net Income
54.6% | 83.0%
Free Cash Flow
48.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.4
FCF per Share
$-1.2
Short interest
2.1%
Employees
14
Rev per Employee
$0.0
Show more

Is HilleVax a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

HilleVax Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a HilleVax forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a HilleVax forecast:

Hold
57%
Sell
43%

Financial data from HilleVax

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
23% 23%
-
- Research and Development Expense 29 29
74% 74%
-
-50 -50
65% 65%
-
- Depreciation and Amortization 2.67 2.67
18% 18%
-
EBIT (Operating Income) EBIT -52 -52
64% 64%
-
Net Profit -71 -71
55% 55%
-

In millions USD.

Don't miss a Thing! We will send you all news about HilleVax directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

HilleVax Stock News

Neutral
GlobeNewsWire
6 days ago
NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of HilleVax, Inc. (NasdaqGS: HLVX) to XOMA Royalty Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HilleVax will receive $1.95 in cash per...
Neutral
Business Wire
17 days ago
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the ...
Neutral
GlobeNewsWire
19 days ago
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Second Quarter Financial Results As of June 30, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $15...
More HilleVax News

Company Profile

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.

Head office United States
CEO Robert Hershberg
Employees 14
Founded 2020
Website www.hillevax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today